Alterations in the gut microbiota are associated with changes in intestinal antibody production in KK-Ay mice developing type 2 diabetes
By
Miho Chikazawa
Ken-Ichiro Minato
June 30, 2026
Clinical Scorecard: Changes in Gut Microbiota Correlate with Intestinal Antibody Production Variations in KK-Ay Mice with Type 2 Diabetes
At a Glance
Category Detail
Condition Type 2 Diabetes Mellitus (T2DM) Key Mechanisms Alterations in intestinal immune system and gut microbiota interactions affecting antibody production. Target Population KK-Ay mice, a model for spontaneous T2DM. Care Setting Experimental research on diabetes mechanisms.
Key Highlights
KK-Ay mice exhibit increased IgA antibody production in the intestine. Changes in gut microbiota composition correlate with intestinal immune responses. Inflammatory cytokines are elevated in KK-Ay mice, indicating a chronic inflammatory state. IgA antibodies play a role in maintaining intestinal homeostasis and mitigating diabetes severity. Both T cell-dependent and T cell-independent pathways are involved in IgA production. Guideline-Based Recommendations
Diagnosis
Monitor for hyperglycemia and hyperinsulinemia as early features of T2DM. Management
Consider the role of intestinal immunity and microbiota in T2DM management strategies. Monitoring & Follow-up
Assess levels of inflammatory mediators in T2DM patients. Risks
Chronic inflammation may exacerbate insulin resistance and other diabetes symptoms. Patient & Prescribing Data
KK-Ay mice as a model for studying T2DM.
Regulation of immune responses and inflammation may be beneficial in T2DM.
Clinical Best Practices
Investigate the gut microbiota's role in T2DM for potential therapeutic targets. Focus on immune system regulation to prevent or mitigate T2DM progression. Related Resources & Content
